Citations

Clear

13603 citation(s) found for "_, _".

Pulmonary Alveolar Proteinosis: Clinical Characteristics and Whole Lung Lavage Utilization Trends, a Nationwide Study
Labban, M. El, Eid, Kevin , Zibaoui, Roba El , Eid, K., Ataya, Ali

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1817-A1817

10.1164/ajrccm.2025.211.abstracts.a1817 Get It

Abstract Rationale: Pulmonary alveolar proteinosis (PAP) is a rare lung disorder characterized by the accumulation of surfactant in the alveoli, primarily seen in autoimmune PAP (aPAP), which accounts for over 90% of cases. The COVID-19 pandemic has highlighted the potential for viral infections to exacerbate or induce PAP, complicating diagnosis and treatment. Objective: This study aims to provide updated clinical and demographic characteristics of patients with pulmonary alveolar proteinosis (PAP) and to analyze trends in the use of whole lung lavage before the COVID-19 pandemic, as well as assess the impact of the pandemic on WLL utilization. Methods: Using data from the National Inpatient Sample from 2017 to 2021, the authors identified PAP, other diagnoses, and procedures. using the respective ICD-10 codes. Statistical analysis was performed on the trends of whole lung lavage and other outcomes across the five years. Results: A total of 3,030 hospitalized PAP patients were included in the study, with demographic and clinical characteristics reported for the cohort. Although the use of WLL increased from 11.55% pre-pandemic to 14.67% during the pandemic, this difference was not statistically significant. However, there was a significant rise in the incidence of acute respiratory failure during the pandemic (35.7% vs. 45.78%, p = 0.02). While transbronchial lung biopsies increased and open lung biopsies declined, these trends were not statistically significant. Conclusion: In recent years, despite a decline in the use of WLL for treating PAP and open lung biopsies for diagnosis, the rates have risen due to the impact of the COVID-19 pandemic.
Association of Obesity With Mortality, ARDS, and Thromboembolism in ICU Patients on Prolonged Ventilation
LOHANA, ABHI , Versha, Fnu, Kumar, B., Khawar, Muhammad Umair , Patel, Viral , Akbar, Usman Ali , Chander, Subhash

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1504-A1504

10.1164/ajrccm.2025.211.abstracts.a1504 Get It

Abstract Introduction: Obesity's increasing prevalence significantly impacts Intensive Care Unit (ICU) patient outcomes, especially for those requiring prolonged mechanical ventilation. This study investigates the effect of Body Mass Index (BMI) on mortality and complications—such as acute respiratory distress syndrome (ARDS), pulmonary embolism (PE), and deep vein thrombosis (DVT)—in ICU patients intubated for over 96 hours. Methods: We conducted a retrospective cohort study using the TriNetX database to identify patient populations with relevant ICD codes. Patients who had received anticoagulation and had been on mechanical ventilation for more than 96 hours were included. Cohort 1 consisted of patients with a BMI of 30-44.9 kg/m² (n = 70,379), and Cohort 2 included patients with a BMI of 18.5-29.9 kg/m² (n = 111,054). Both cohorts were matched using propensity score matching (PSM), resulting in balanced groups of 47,233 patients. The mean age was 64.3 ± 15.1 years in Cohort 1 and 64.5 ± 16.5 years in Cohort 2, with a male predominance of 57.9% in both cohorts after matching. Outcomes (mortality, PE, DVT, and ARDS) were identified using ICD-10 codes and analyzed on Days 14, 30, and 90. Results: Higher BMI was associated with increased all-cause mortality across all measured time points. By Day 14, mortality was 23.0% in Cohort 1 versus 19.2% in Cohort 2 (RiskRatio [RR]: 1.196; 95% CI: 1.166-1.226). By Day 90, mortality reached 37.6% in Cohort 1 compared to 32.6% in Cohort 2 (RR: 1.151; 95% CI: 1.132-1.171). Additionally, the risk of developing ARDS was higher in Cohort 1, with statistically significant risk ratios observed on Day 14 (RR: 1.117; 95% CI: 1.020-1.222) and Day 30 (RR: 1.094; 95%CI: 1.010-1.186). PE risk in Cohort 1 significantly increased by Day 30 (RR: 1.119; 95% CI: 1.008-1.243), while DVT risk was also elevated in Cohort 1 at both Day 14 (RR:1.140; 95% CI: 1.037-1.253) and Day 30 (RR: 1.129; 95% CI: 1.040-1.224). Conclusion: Higher BMI in mechanically ventilated ICU patients intubated for more than 96 hours is associated with increased mortality and a higher incidence of complications, including ARDS, PE, and DVT. This study contributes to our understanding of BMI's impact on ICU outcomes, highlighting critical areas for improved clinical management in this population and the need for targeted interventions in obese ICU patients, such as optimized respiratory support and monitoring for thromboemboliccomplications.
Lung Function Improvement in Patients With Uncontrolled, Moderate-to-Severe Asthma Treated With Benralizumab: A New, Retrospective Analysis of the Pooled Sirocco and Calima Studies
Carstens, Donna, Harrison, Andrew , Meyers, Deborah A. , Cohen, David , Koury, Jason , Bleecker, Eugene R. , Koury, J., Menzies-Gow, Andrew N

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1052-A1052

10.1164/ajrccm.2025.211.abstracts.a1052 Get It

Abstract RATIONALE: Airway remodeling, a key characteristic of severe asthma, leads to progressive loss of lung function and incomplete reversibility of airflow obstruction. We examined the effect of benralizumab on lung function in patients from the pooled SIROCCO (Bleecker ER, et al. Lancet 2016; PMID: 27609408) and CALIMA (FitzGerald JM, et al. Lancet 2016; PMID: 27609406) studies, utilizing a new analysis of spirometry to highlight important changes in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) throughout the studies. METHODS: This retrospective analysis pooled data from the randomized, placebo-controlled, double-blind Phase 3 SIROCCO and CALIMA studies. SIROCCO enrolled patients with severe asthma, while CALIMA enrolled patients with moderate-to-severe asthma, both with a planned 2:1 randomization for baseline blood eosinophils ≥300 cells/μL versus <300 cells/μL. All patients (aged 12-75 years) had ≥2 exacerbations in the previous year, despite use of medium- to high-dose inhaled corticosteroids plus additional controllers. Patients in this analysis received subcutaneous benralizumab 30 mg every 8 weeks (Q8W; first three doses given every 4 weeks) for 48 weeks in SIROCCO and 56 weeks in CALIMA. The changes in FEV1 and FVC following bronchodilator (BD) were measured at baseline and study end. Effects on FEV1 and FVC were further stratified by baseline eosinophil count (≥300 cells/μL or <300 cells/μL). Results are reported as mean (standard deviation). RESULTS: Overall, 839 patients received benralizumab Q8W; 557 had a baseline eosinophil count of ≥300 cells/μL and 282 had <300 cells/μL. At baseline, pre- and post-BD FEV1 were 1722 mL (615; n=837) and 2128 mL (755; n=813). At study end, pre- and post-BD FEV1 were 2029 mL (756; n=735) and 2225 mL (800; n=738). At baseline, pre- and post-BD FVC were 2865 mL (905; n=837) and 3285 mL (971; n=813). At study end, pre- and post-BD FVC were 3214 mL (1010; n=735) and 3379 mL (1021; n=738). Pre-BD FEV1 and FVC improved by 307 mL and 349 mL and post-BD FEV1 and FVC improved by 97 mL and 94 mL between baseline and study end, respectively. Stratified by baseline eosinophil count, findings were similar in both groups (Figure). CONCLUSIONS: Benralizumab treatment resulted in both improved FEV1 and FVC while maintaining BD response in patients with uncontrolled, moderate-to-severe asthma. Improvements were seen in patients with baseline eosinophil counts of both ≥300 cells/μL and <300 cells/μL. These results may reflect reduced hyperinflation, potentially due to improved airway inflammation and mucus plugging.
Arthroscopic Hip Transcapsular, Translabral Delivery of Orthobiologics for Single‐Stage Cartilage Repair
Hevesi, Mario , Kang, Louis , Krych, Aaron J. , Krych, Aaron J , Hevesi, Mario , Kang, Louis S

Mayo Clinic

Arthroscopy Techniques | May 10, 2025 | Volume: 14 | Issue: 7 | Pages: No page available

10.1016/j.eats.2025.103587 | PMID 40822174 Get It

Abstract Hip chondral defects often are encountered at the time of hip arthroscopy and can result in substantial pain and dysfunction. With the evolution of cell‐based techniques, there is growing interest in single‐stage, arthroscopic treatment of such chondral lesions. Arthroscopic orthobiologic delivery remains technically challenging, given the constrained and concave nature of the acetabulum and the need to perform instrumentation taking into account nearby structures such as the articular surface, hip capsule, and labrum. In this Technical Note, we describe our preferred method for arthroscopic delivery of orthobiologics at the time of single‐stage cartilage repair, which allows for needle‐based transcapsular, translabral access of hip chondral defects for both the acetabulum and femoral head. Technique Video video See video under supplementary data.
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Kumar, Shaji , Adekola, Kehinde , Anderson, Larry , Costello, Caitlin , D’Angelo, Christopher R. , Derman, Benjamin A. , Elsedawy, Noura, Godara, Amandeep , Godby, Kelly, Hillengaß, Jens , Holmberg, Leona , Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Larson, Sarah , Liedtke, Michaela , Omel, James, Robinson, Timothy, Valent, Jason , Varshavsky‐Yanovsky, Asya, Kovách, E, Holmberg, Leona , Anderson, Larry D. , Anderson, Larry D , Derman, Benjamin A , Callander, Natalie S. , Baljević, Muhamed , Baz, Rachid , Campagnaro, Erica , Devarakonda, Srinivas , Kang, Yubin , Lee, Hans C. , Martin, Thomas G. , Rosenberg, Aaron , Schroeder, Mark A. , Sherbenou, Daniel W , Suvannasankha, Attaya , Valent, Jason Neil , Vogl, Dan T. , Kovach, Emily, Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2025 | Volume: 23 | Issue: 5 | Pages: 132-140

10.6004/jnccn.2025.0023 | PMID 40340857 Get It

The NCCN Guidelines for Multiple Myeloma (MM) provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with MM. These NCCN Guidelines Insights highlight the important updates and changes specific to systemic therapy for patients with newly diagnosed as well as previously treated MM included in Version 1.2025 of the NCCN Guidelines for MM.
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Ajani, Jaffer A. , D’Amico, Thomas A., Bentrem, David J., Corvera, Carlos U. , Das, Prajnan , Enzinger, Peter C. , Enzler, Thomas , Gerdes, Hans, Grierson, Patrick , Hofstetter, Wayne L. , Ilson, David H. , Jalal, Shadia I. , Kleinberg, Lawrence , Lacy, Jill , Lee, Byrne , Licciardi, Frank, Ly, Quan P. , Matsukuma, Karen , McNamara, Michael, Mukherjee, Sarbajit , Mulcahy, Mary F. , Reddi, Deepti , Reznik, Scott I. , Roses, Robert E. , Strong, Vivian E. , Su, Stacey, Uboha, Nataliya V. , Willett, Christopher G. , Yoon, Harry H. , McMillian, Nicole R., Stein, MaryElizabeth , Gupta, Garima , Ajani, Jaffer A , Bentrem, David J. , Gibson, Michael K. , Gupta, Garima , Kim, Sunnie S. Y. , Klempner, Samuel J. , Lloyd, Shane , Merkow, Ryan P. , Perry, Kyle A. , Pimiento, José M. , Reddi, Deepti , Wainberg, Zev A. , Woo, Yanghee

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2025 | Volume: 23 | Issue: 5 | Pages: 169-191

10.6004/jnccn.2025.0022 | PMID 40341199 Get It

Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease.
JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
Kang, Di , Wang, Yanping , Lin, Yiwei , Wee, Wen , Morgensztern, Daniel , Leventakos, Konstantinos , Bi, Chao , Ding, Yuli , Xiong, Jing , Yan, Man , Sun, Xin , Wang, Peng George , Ma, Cunbo , Wang, Yinxiang , Ma, Wen Wee , Wang, Peng , Ding, Yuli

Mayo Clinic

Clinical Cancer Research | May 7, 2025 | Volume: 31 | Issue: 14 | Pages: 3019-3032

10.1158/1078-0432.ccr-24-3691 | PMID 40333694 Get It

Abstract Purpose: Recent advances have seen the development of targeted therapeutics against the receptor tyrosine kinase (RTK)/RAS/MAPK pathway, which, when aberrantly activated, drives the malignant transformation of many cancer indications. However, the efficacy of inhibitors targeting single molecules is dampened by pathway feedback activation and acquired drug resistance. We seek to evaluate the application of JAB-3312 (sitneprotafib), a potent inhibitor of SHP2, in RTK/RAS/MAPK pathway–targeted combination therapies. Furthermore, SHP2 plays a vital role in PD-1–mediated immunosuppression. The rational combination of JAB-3312 with PD-1 blocking therapies is also explored. Experimental Design: Biochemical and cellular assays were applied to evaluate the potency of JAB-3312 in SHP2 inhibition. Tumor cell lines and cell line– and patient-derived xenografts were used to test different combinations of JAB-3312 with KRASG12C, MEK, EGFR, and PD-1 inhibitors. Results: JAB-3312 produced potent in vitro inhibition of SHP2 activity and downstream ERK phosphorylation, with IC50 values of 1.44 nmol/L and 0.68 to 4.84 nmol/L, respectively. When used in combination, JAB-3312 significantly increased the antitumor activity of the KRASG12C inhibitor glecirasib in naïve and resistant models. The combination of JAB-3312 with MEK inhibitors significantly delayed RTK signaling reactivation and enhanced tumor growth inhibition in KRAS-mutated cancer models. The JAB-3312–osimertinib combination exhibited great efficacy in osimertinib-resistant non–small cell lung cancer models. Additionally, JAB-3312 enhanced the efficacy of PD-1 blockade therapies by promoting an antitumor microenvironment. Representative cases of patients who responded to the combination therapies from two ongoing clinical trials (NCT05288205 and NCT04720976) were reported. Conclusions: JAB-3312 in combination with RTK/RAS/MAPK or PD-1 blockade therapies is a promising strategy that warrants further clinical investigation.
2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
Sammaritano, Lisa R. , Askanase, Anca , Bermas, Bonnie L. , Dall’Era, Maria , Duarte‐García, Alí , Hiraki, Linda T. , Rovin, Brad H. , Alvarado, Anthony, Aranow, Cynthia , Broder, Anna , Chowdhary, Vaidehi , Contreras, Gabriel, Felix, Christele, Gibson, Keisha L. , Hersh, Aimee O. , Kalunian, Kenneth , Rollins, Brandi , Smith, Benjamin J. , Thomas, Asha , Timlin, Homa , Ward, Michael D. , Cunha, Joanne S., DeQuattro, Kimberly , Figueroa‐Parra, Gabriel , Greco, Jessica , Cuéllar‐Gutiérrez, María C. , Iyer, Priyanka , Johannemann, Andrew, Jorge, April , Kasturi, S.Psi. Taufik , Khawandi, Jana , Legge, Alexandra , Liang, Kelly V. , Lockwood, Megan M. , Sánchez-Rodríguez, Alain , Turgunbaev, Marat, Williams, Jessica N. , Turner, Amy S. , Aranow, Cynthia , Barnado, April , Brunner, Hermine I , Ferucci, Elizabeth D , Hersh, Aimee O , Smith, Benjamin J , Wallace, Daniel J , Bartels, Christie M , DeQuattro, Kimberly , Figueroa-Parra, Gabriel , Garg, Shivani , Cuéllar-Gutiérrez, María C, Jorge, April , Kasturi, Shanthini , Kawtharany, Hassan , Kirou, Kyriakos A , Lockwood, Megan M , Sanchez-Rodriguez, Alain , Williams, Jessica N , Turner, Amy S , Duarte-García, Alí , Rovin, Brad H , Askanase, Anca , Bermas, Bonnie , Son, Mary Beth F. , Barnado, April , Contreras, Gabriel, Ferucci, Elizabeth D. , Izmirly, Peter , Kamen, Diane L. , Rollins, Brandi, Thomas, Asha, Azzam, Muayad , Bartels, Christie M. , Fava, Andrea , Garg, Shivani , Kawtharany, Hassan , Kirou, Kyriakos A. , Mustafa, Reem A

Mayo Clinic

Arthritis & Rheumatology | May 7, 2025 | Volume: 77 | Issue: 9 | Pages: 1115-1135

10.1002/art.43212 | PMID 40331662 Get It

ObjectiveThe objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis.MethodsThe Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus ≥70% on the direction (for or against) and strength (strong or conditional) of each recommendation.ResultsWe present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus‐based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving complete renal response.ConclusionThis guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual patient.
Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma
Cheville, John C. , Kopp, Karla, Torell, Nate R, Lavoie, Roxane R. , Farrell, Ava, Jaszewski, Brandy L., Jenkins, Sarah M. , Dasari, Surendra , Menon, Santosh, Whaley, Rumeal D. , Boorjian, Stephen A. , Pagliaro, Lance C. , Gupta, Sounak , Lucien, Fabrice , Kopp, Karla J, Smith, Carin Y , Tekin, Burak , Lucien, Fabrice , McCarthy, Michael, Dong, Haidong , Smith, Carin Y. , Erickson, Lori A, Guo, Ruifeng

Mayo Clinic

American Journal of Clinical Pathology | May 6, 2025 | Volume: 163 | Issue: 6 | Pages: 898-908

10.1093/ajcp/aqaf022 | PMID 40327767 Get It

Abstract Objectives We aimed to assess the expression of biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma (pSCC). Methods Our archive was queried for patients who had a penectomy for pSCC between 2000 and 2022. Primary tumors were immunostained for B7-H3 and NKG7, while metastatic specimens were immunostained for TROP2 and nectin-4. Expression of PD-L1, TROP2, and nectin-4 in primary tumors was previously characterized. H-scores (0-300) were used to quantify expression. Associations between biomarkers, tumor-infiltrating lymphocytes (TILs), and clinicopathologic and outcome parameters were evaluated. Results For both TROP2 and nectin-4, H-scores within the lymph node metastases were higher compared to those within the primary tumors (mean, 264.5 vs 244.8, P = .0003; mean, 170.6 vs 146.7, P = .05, respectively; 33 paired specimens). For B7-H3 (n = 107), 32.7% of the primary tumors had an H-score of more than 0. In 34.8% of the cases, NKG7 expression was observed in 25% to 50% of the TILs. A significant association was noted between TIL density, B7-H3, NKG7, and PD-L1 expression. Conclusions Therapeutic strategies targeting TROP2 and nectin-4 hold promise for patients with advanced pSCC. The potential of PD-L1, B7-H3, and NKG7 for predicting response to immunomodulatory treatment warrants further research.
Dual‐stream algorithms for dementia detection: Harnessing structured and unstructured electronic health record data, a novel approach to prevalence estimation
Liu, Ming , Carver, Alison , Rocca, Walter A. , Lu, Alicia , Siostrom, Kristy, Roberts, Helene E., Chong, Trevor T.‐J. , Murray, Anne M. , Ravipati, Tanya , O’Bree, Bridget , Collyer, Taya Annabelle , Beare, Richard , Andrew, Nadine E. , Ung, David , Ilomäki, Jenni , Bell, J. Simon , Thrift, Amanda G. , Sauver, Jennifer L. St. , Moran, Chris , Roberts, Helene, Srikanth, Velandai

Mayo Clinic

Alzheimer's & Dementia | May 6, 2025 | Volume: 21 | Issue: 5 | Pages: No page available

10.1002/alz.70132 | PMID 40325920 Get It

AbstractINTRODUCTIONIdentifying individuals with dementia is crucial for prevalence estimation and service planning, but reliable, scalable methods are lacking. We developed novel set algorithms using both structured and unstructured electronic health record (EHR) data, applying Diagnostic and Statistical Manual of Mental Disorders criteria for dementia case identification.METHODSOur cohort (n = 1082) included individuals aged ≥ 60 with dementia identified through specialist clinics and a comparison group without dementia. Clinicians from Australia and the United States informed predictor selection. We developed algorithms through a biostatistics stream for structured data and a natural language processing (NLP) stream for text, synthesizing results via logistic regression.RESULTSThe final structured model retained 16 variables (area under the receiver operating characteristic curve [AUC] 0.853, specificity 72.2%, sensitivity 80.6%). NLP classifiers (logistic regression, support vector machine, and random forest models) performed comparably. The final, combined model outperformed all others (AUC = 0.951, P < 0.001 for comparison to structured model).DISCUSSIONEmbedding text‐derived insights within algorithms trained on structured medical data significantly enhances dementia identification capacity.Highlights Algorithmic tools for detection of individuals with dementia are available; however, previous work has used heterogeneous case definitions which are not clinically meaningful, and has relied on proxies such as diagnostic codes or medications for case ascertainment. We used a novel, dual‐stream algorithmic development approach, simultaneously and separately modeling a clinically meaningful outcome (diagnosis of dementia according to specialized clinical impression) using structured and unstructured electronic health record datasets. Our clinically grounded case definition supported the inclusion of key structured variables (such as dementia International Classification of Disease codes and medications) as modeling predictors rather than outcomes. Our algorithms, published in detail to support validation and replication, represent a major step forward in the use of routinely collected data for detection of diagnosed dementia.